Press Releases Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-20 pm EDT			5-day change	1st Jan Change
15.21 ^USD	+1.74%		+6.66%	+69.19%

Mar. 06	Nektar Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4)	RE
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data For Lonvoguran Ziclumeran	CI

Press Releases

Apr. 03	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Mar. 06	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Mar. 04	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran, Hereditary Angioedema Patient-Focused Research at AAAAI 2026	AQ
Mar. 03	Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone	AQ
Mar. 03	Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026	AQ
Mar. 02	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM	AQ
Feb. 26	Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
Feb. 24	Intellia Therapeutics to Participate in Upcoming Investor Conferences	AQ
Feb. 20	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
Feb. 19	Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates	AQ
Feb. 06	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Jan. 28	Cutting DNA, Cutting Edge: Companies Using CRISPR and Other Gene Editing Technologies to Rewrite the Future of Industry and Medicine	AQ
Jan. 27	Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE-2 Phase 3 Clinical Trial in ATTRv-PN	AQ
Jan. 07	Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference	AQ
Jan. 02	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Dec. 08	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Dec. 05	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ
Nov. 11	Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran in Patients with Transthyretin Amyloidosis with Cardiomyopathy	AQ
Nov. 10	Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy	AQ
Nov. 10	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran in Patients with Hereditary Angioedema	AQ
Nov. 08	Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema	AQ
Nov. 06	Intellia Therapeutics Announces Third Quarter 2025 Financial Results and Recent Updates	AQ
25-10-27	Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)	AQ
25-10-06	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
25-10-03	Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	AQ